Trial
NCT05220098
First-in-Human Study of TAK-280 in Participants With Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc.
Condition
Unresectable Locally Advanced or Metastatic Cancer
Intervention
TAK-280
Why stopped
Terminated due to limited anti-cancer activity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-29